JP2015516378A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516378A5
JP2015516378A5 JP2015502028A JP2015502028A JP2015516378A5 JP 2015516378 A5 JP2015516378 A5 JP 2015516378A5 JP 2015502028 A JP2015502028 A JP 2015502028A JP 2015502028 A JP2015502028 A JP 2015502028A JP 2015516378 A5 JP2015516378 A5 JP 2015516378A5
Authority
JP
Japan
Prior art keywords
thioridazine
subject
cytarabine
concentration
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516378A (ja
Filing date
Publication date
Priority claimed from US13/837,115 external-priority patent/US8809299B2/en
Application filed filed Critical
Publication of JP2015516378A publication Critical patent/JP2015516378A/ja
Publication of JP2015516378A5 publication Critical patent/JP2015516378A5/ja
Pending legal-status Critical Current

Links

JP2015502028A 2012-03-28 2013-03-28 癌の処置のための組み合わせ療法 Pending JP2015516378A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261616658P 2012-03-28 2012-03-28
US61/616,658 2012-03-28
US13/837,115 US8809299B2 (en) 2012-03-28 2013-03-15 Combination therapy for the treatment of cancer
US13/837,115 2013-03-15
PCT/CA2013/050255 WO2013143000A1 (en) 2012-03-28 2013-03-28 Combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2015516378A JP2015516378A (ja) 2015-06-11
JP2015516378A5 true JP2015516378A5 (enExample) 2016-05-12

Family

ID=49235839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502028A Pending JP2015516378A (ja) 2012-03-28 2013-03-28 癌の処置のための組み合わせ療法

Country Status (5)

Country Link
US (3) US8809299B2 (enExample)
EP (1) EP2830633A4 (enExample)
JP (1) JP2015516378A (enExample)
CA (1) CA2868629A1 (enExample)
WO (1) WO2013143000A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2680853A4 (en) * 2011-02-28 2014-08-06 Univ Mcmaster TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS
US8809299B2 (en) 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer
WO2015080681A1 (en) * 2013-11-29 2015-06-04 Andac Ahmet Cenk Phenothiazine-pyrimidine-2,4(1 h, 3h)-dione compounds for the treatment of cancer
EP2932969A1 (en) 2014-04-17 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Pancreatic cancer therapy and diagnosis
US10874685B2 (en) 2014-04-17 2020-12-29 The Royal Institution For The Advancement Of Learning/Mcgill University Pancreatic cancer therapy and diagnosis
TWI735413B (zh) * 2014-06-02 2021-08-11 國立陽明交通大學 抗藥性癌症之治療方法
WO2015193902A1 (en) * 2014-06-19 2015-12-23 Sol Efroni Polymorphism in the bcl2 gene determines response to chemotherapy
EP3490554B1 (en) 2016-07-28 2023-07-05 Jiangsu Yahong Meditech Co., Ltd. Uses of dopamine beta-hydroxylase (dbh) inhibitors for the treatment of cancer
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
US11993775B2 (en) * 2020-07-27 2024-05-28 National Cheng Kung University Ubiquitin-specific peptidase 24 inhibitor, medicinal composition and method of delaying or reversing multidrug resistance in cancers using the same
US11827611B2 (en) 2020-07-27 2023-11-28 National Cheng Kung University Ubiquitin-specific peptidase 24 inhibitor, medicinal composition including the same and method of delaying or reversing multidrug resistance in cancers using the same
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN114031574A (zh) * 2021-11-08 2022-02-11 复旦大学附属肿瘤医院 哌罗匹隆及其衍生物在制备抗肿瘤药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072824A1 (en) 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US20040116407A1 (en) * 2002-07-11 2004-06-17 Alexis Borisy Combinations of drugs for the treatment of neoplasms
AU2004273910A1 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
EP2680853A4 (en) * 2011-02-28 2014-08-06 Univ Mcmaster TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS
US8809299B2 (en) 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2015516378A5 (enExample)
WO2012143497A3 (de) Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
WO2013087716A3 (de) Fgfr- binder -wirkstoff konjugate und ihre verwendung
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
PH12018500023A1 (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
UA113774C2 (xx) Полімерні наночастинки, що складаються з фінастериду та міноксидилу, спосіб їх виготовлення, водна суспензія, що їх містить, фармацевтична композиція на їх основі та їх застосування
EP2133365A3 (en) Compositions and methods for the treatment of infections and tumors
WO2010063011A3 (en) Methods for the treatment of infections and tumors
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
NZ707377A (en) Combination therapy methods for treating proliferative diseases
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
JP2016501013A5 (enExample)
WO2011017195A3 (en) Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
JP2012519182A5 (enExample)
JP2010523696A5 (enExample)
WO2015034678A3 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
JP2015528479A5 (enExample)
EA201590546A1 (ru) Способы лечения заболеваний, связанных с волосами
EP4233536A3 (en) Method for enhancing tumor growth
AR059225A1 (es) Sal de citrato, proceso de preparacion y su actividad en terapia
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
WO2012075244A3 (en) Use of hemoglobin effectors to increase the bioavailability of therapeutic gases